The Experts below are selected from a list of 6 Experts worldwide ranked by ideXlab platform

Eric M Tichy - One of the best experts on this subject based on the ideXlab platform.

  • RhoD Immune Globulin products for prevention of alloimmunization during pregnancy
    American Journal of Health-system Pharmacy, 2015
    Co-Authors: Samuel L Aitken, Eric M Tichy
    Abstract:

    Purpose The pharmacologic properties of Rhesus (Rh) Immune Globulin (RhIG) and clinical data on its effectiveness in preventing Rh-antigen alloimmunization in pregnant women are reviewed. Summary RhIG is a human plasma derivative that targets red blood cells (RBCs) positive for RhO antigen (also called D antigen). In the United States and other countries, the widespread use of RhIG has markedly reduced the occurrence of hemolytic disease of the fetus and newborn (HDFN), a devastating condition caused by D-antigen sensitization of a pregnant woman via exposure to fetal RBCs (usually during detachment of the placenta in labor) that results in a maternal Immune response leading to severe hemolysis in the fetus. Routine administration of RhIG at 26–30 weeks’ gestation and again within 72 hours of delivery has been shown to be highly effective in preventing maternal Rh alloimmunization, with very low rates of D-antigen sensitization (in the range of 0–2.2%) reported in multiple studies of at-risk women. The four RhIG products currently available in the United States have common clinical indications but differ in certain attributes. Pharmacists can play an important role in guiding other clinicians on the rationale for the use of RhIG, important differences between products, and appropriate timing of RhIG therapy. Conclusion Routine administration of RhIG to women at risk for Rh alloimmunization is clinically effective and has made HDFN a rare clinical event. The available RhIG products are not the same and should be carefully reviewed to ensure that they are administered safely.

Samuel L Aitken - One of the best experts on this subject based on the ideXlab platform.

  • RhoD Immune Globulin products for prevention of alloimmunization during pregnancy
    American Journal of Health-system Pharmacy, 2015
    Co-Authors: Samuel L Aitken, Eric M Tichy
    Abstract:

    Purpose The pharmacologic properties of Rhesus (Rh) Immune Globulin (RhIG) and clinical data on its effectiveness in preventing Rh-antigen alloimmunization in pregnant women are reviewed. Summary RhIG is a human plasma derivative that targets red blood cells (RBCs) positive for RhO antigen (also called D antigen). In the United States and other countries, the widespread use of RhIG has markedly reduced the occurrence of hemolytic disease of the fetus and newborn (HDFN), a devastating condition caused by D-antigen sensitization of a pregnant woman via exposure to fetal RBCs (usually during detachment of the placenta in labor) that results in a maternal Immune response leading to severe hemolysis in the fetus. Routine administration of RhIG at 26–30 weeks’ gestation and again within 72 hours of delivery has been shown to be highly effective in preventing maternal Rh alloimmunization, with very low rates of D-antigen sensitization (in the range of 0–2.2%) reported in multiple studies of at-risk women. The four RhIG products currently available in the United States have common clinical indications but differ in certain attributes. Pharmacists can play an important role in guiding other clinicians on the rationale for the use of RhIG, important differences between products, and appropriate timing of RhIG therapy. Conclusion Routine administration of RhIG to women at risk for Rh alloimmunization is clinically effective and has made HDFN a rare clinical event. The available RhIG products are not the same and should be carefully reviewed to ensure that they are administered safely.

Laura L. Klein - One of the best experts on this subject based on the ideXlab platform.

  • A curious case of anti-D antibody titer.
    Journal of Midwifery & Women's Health, 2009
    Co-Authors: Jennifer G. Hensley, Katherine P. Coughlin, Laura L. Klein
    Abstract:

    RhD alloimmunization remains a threat to 1% of the 10% of RhD-negative women in the United States who are giving birth to RhD-positive fetuses despite routine antenatal and postpartum administration of RhoD Immune Globulin (RhIG). This report examines the clinical course of an RhD-negative woman who developed a high anti-D antibody titer during her pregnancy while carrying an RhD-positive female fetus yet had a negative antibody screen at the time she gave birth. Although she delivered a healthy newborn unaffected by hemolytic disease, subsequent pregnancies will be treated as though she is RhD alloimmunized. The discussion below includes possible causes for the abrupt rise in this woman's anti-D antibody titer, a review of the complex Rh system and cellular anamnestic response, and current fetal surveillance for hemolytic disease of the fetus and newborn.

Jennifer G. Hensley - One of the best experts on this subject based on the ideXlab platform.

  • A curious case of anti-D antibody titer.
    Journal of Midwifery & Women's Health, 2009
    Co-Authors: Jennifer G. Hensley, Katherine P. Coughlin, Laura L. Klein
    Abstract:

    RhD alloimmunization remains a threat to 1% of the 10% of RhD-negative women in the United States who are giving birth to RhD-positive fetuses despite routine antenatal and postpartum administration of RhoD Immune Globulin (RhIG). This report examines the clinical course of an RhD-negative woman who developed a high anti-D antibody titer during her pregnancy while carrying an RhD-positive female fetus yet had a negative antibody screen at the time she gave birth. Although she delivered a healthy newborn unaffected by hemolytic disease, subsequent pregnancies will be treated as though she is RhD alloimmunized. The discussion below includes possible causes for the abrupt rise in this woman's anti-D antibody titer, a review of the complex Rh system and cellular anamnestic response, and current fetal surveillance for hemolytic disease of the fetus and newborn.

Katherine P. Coughlin - One of the best experts on this subject based on the ideXlab platform.

  • A curious case of anti-D antibody titer.
    Journal of Midwifery & Women's Health, 2009
    Co-Authors: Jennifer G. Hensley, Katherine P. Coughlin, Laura L. Klein
    Abstract:

    RhD alloimmunization remains a threat to 1% of the 10% of RhD-negative women in the United States who are giving birth to RhD-positive fetuses despite routine antenatal and postpartum administration of RhoD Immune Globulin (RhIG). This report examines the clinical course of an RhD-negative woman who developed a high anti-D antibody titer during her pregnancy while carrying an RhD-positive female fetus yet had a negative antibody screen at the time she gave birth. Although she delivered a healthy newborn unaffected by hemolytic disease, subsequent pregnancies will be treated as though she is RhD alloimmunized. The discussion below includes possible causes for the abrupt rise in this woman's anti-D antibody titer, a review of the complex Rh system and cellular anamnestic response, and current fetal surveillance for hemolytic disease of the fetus and newborn.